Methods of using interleukin-2 agents
AssigneesVisterra, Inc., The General Hospital Corporation
InventorsScott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan, Thiago de Jesus Borges, Leonardo Vidal Riella
Life of this patent
Estimating the term…
Abstract
IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
Claims24
A method of treating or preventing a transplantation rejection in a subject, comprising administering to the subject an effective amount of an IL-2 agent,
- wherein the IL-2 agent is an IL-2 variant or an IL-2 fusion protein comprising the IL-2 variant, and wherein the IL-2 variant comprises:
- (i) the amino acid substitution H16L or H16N, and/or the amino acid substitution I92S;
- and
- (ii) the amino acid substitutions V69A, Q74P, and C125S,
- corresponding to human IL-2 (SEQ ID NO:
- 1031),
- thereby treating or preventing the transplantation rejection in the subject.
A method of treating a transplantation rejection in a subject, comprising administering to the subject an effective amount of an IL-2 agent,
- wherein the IL-2 agent is an IL-2 variant or an IL-2 fusion protein comprising the IL-2 variant, and wherein the IL-2 variant comprises:
- (i) the amino acid substitution H16L or H16N, and/or the amino acid substitution I92S;
- and
- (ii) the amino acid substitutions V69A, Q74P, and C125S,
- corresponding to human IL-2 (SEQ ID NO:
- 1031),
- thereby treating the transplantation rejection in the subject.
A method of conditioning a subject prior to a transplantation, comprising administering to the subject an effective amount of an IL-2 agent,
- wherein the IL-2 agent is an IL-2 variant or an IL-2 fusion protein comprising the IL-2 variant, and wherein the IL-2 variant comprises:
- (i) the amino acid substitution H16L or H16N, and/or the amino acid substitution I92S;
- and
- (ii) the amino acid substitutions V69A, Q74P, and C125S,
- corresponding to human IL-2 (SEQ ID NO:
- 1031),
- thereby conditioning the subject prior to transplantation.
A method of inducing and/or modulating (e.g., increasing) immunosuppression in a subject, comprising administering to the subject an effective amount of an IL-2 agent,
- wherein the subject has undergone, is undergoing, or will receive a transplantation,
- wherein the IL-2 agent is an IL-2 variant or an IL-2 fusion protein comprising the IL-2 variant, and wherein the IL-2 variant comprises:
- (i) the amino acid substitution H16L or H16N, and/or the amino acid substitution I92S;
- and
- (ii) the amino acid substitutions V69A, Q74P, and C125S,
- corresponding to human IL-2 (SEQ ID NO:
- 1031),
- thereby inducing and/or modulating (e.g., increasing) immunosuppression in the subject.
A method of selectively increasing T regulatory cells in a subject, comprising administering to the subject an effective amount of an IL-2 agent,
- wherein the subject has undergone, is undergoing, or will receive a transplantation (e.g., a skin transplantation), and
- wherein the IL-2 agent is an IL-2 variant or an IL-2 fusion protein comprising the IL-2 variant, and wherein the IL-2 variant comprises:
- (i) the amino acid substitution H16L or H16N, and/or the amino acid substitution I92S;
- and
- (ii) the amino acid substitutions V69A, Q74P, and C125S,
- corresponding to human IL-2 (SEQ ID NO:
- 1031),
- thereby selectively increasing T regulatory cells in the subject.
A method of treating a subject, comprising administering to the subject an effective amount of an IL-2 agent, and providing to the subject a transplantation (e.g., a skin transplantation), thereby treating the subject.
Dependencies are inferred from the claim text.